These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 23660746)

  • 1. Effect of bortezomib in combination with cisplatin and 5‑fluorouracil on 4T1 breast cancer cells.
    Yerlikaya A; Altıkat S; Irmak R; Cavga FZ; Kocacan SA; Boyaci I
    Mol Med Rep; 2013 Jul; 8(1):277-81. PubMed ID: 23660746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer agent ukrain and bortezomib combination is synergistic in 4T1 breast cancer cells.
    Savran B; Yerlikaya A; Erdoğan E; Genç O
    Anticancer Agents Med Chem; 2014 Mar; 14(3):466-72. PubMed ID: 23919744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
    Yerlikaya A; Erin N
    Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
    Wang X; Feng X; Wang J; Shao N; Ji C; Ma D; Henter JI; Fadeel B; Zheng C
    Anticancer Drugs; 2014 Mar; 25(3):282-8. PubMed ID: 24300915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
    Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
    Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
    Fujita T; Doihara H; Washio K; Ino H; Murakami M; Naito M; Shimizu N
    Anticancer Drugs; 2007 Jul; 18(6):677-86. PubMed ID: 17762396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
    Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
    Horton TM; Gannavarapu A; Blaney SM; D'Argenio DZ; Plon SE; Berg SL
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):13-23. PubMed ID: 16292537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
    Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
    Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells.
    Duechler M; Linke A; Cebula B; Shehata M; Schwarzmeier JD; Robak T; Smolewski P
    Eur J Haematol; 2005 May; 74(5):407-17. PubMed ID: 15813915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.
    Wagenblast J; Hambek M; Baghi M; Gstöttner W; Strebhardt K; Ackermann H; Knecht R
    J Cancer Res Clin Oncol; 2008 Mar; 134(3):323-30. PubMed ID: 17701215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.
    Sato A; Asano T; Ito K; Asano T
    Urology; 2012 Apr; 79(4):966.e13-21. PubMed ID: 22296623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib as a therapeutic candidate for neuroblastoma.
    Armstrong MB; Schumacher KR; Mody R; Yanik GA; Opipari AW; Castle VP
    J Exp Ther Oncol; 2008; 7(2):135-45. PubMed ID: 18771087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.
    Sato A; Asano T; Ito K; Asano T
    J Urol; 2012 Dec; 188(6):2410-8. PubMed ID: 23088964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
    Sato A; Asano T; Ito K; Sumitomo M; Asano T
    BJU Int; 2012 Apr; 109(8):1258-68. PubMed ID: 21895936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
    Hutter G; Rieken M; Pastore A; Weigert O; Zimmermann Y; Weinkauf M; Hiddemann W; Dreyling M
    Ann Hematol; 2012 Jun; 91(6):847-56. PubMed ID: 22231280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effects of combination treatment with bortezomib and doxorubicin in human neuroblastoma cell lines.
    Du BY; Song W; Bai L; Shen Y; Miao SY; Wang LF
    Chemotherapy; 2012; 58(1):44-51. PubMed ID: 22327308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.